Completed

Iscar for Supplemental Care in Stage IV Lung Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Lung Diseases+4

+ Lung Neoplasms

+ Neoplasms

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: September 2001
See protocol details

Summary

Principal SponsorNational Center for Complementary and Integrative Health (NCCIH)
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2001

Actual date on which the first participant was enrolled.

See Brief Summary

Official TitleIscar for Supplemental Care in Stage IV Lung Cancer 
Principal SponsorNational Center for Complementary and Integrative Health (NCCIH)
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

36 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Lung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic Neoplasms

Criteria

Inclusion Criteria: * Stage IV NSCLC patients who receive standard chemotherapy Exclusion criteria: * Known allergy to Viscum Album L. * Concomitant use of other mistletoe products * Concomitant use of mushroom glucan and proteoglycan extracts * Concomitant use of thymus extract products * Inability to self-report quality of life utilizing assessment tools * Ongoing steroid or ACTH therapy * Co-morbid immunocompromised state * Pregnancy * Participation in other clinical trials

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Thomas Jefferson University

Philadelphia, United StatesSee the location
CompletedOne Study Center